Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)

Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC) has changed considerably. Persistent androgen receptor (AR) signaling has been identified as a target for novel therapies and reengages the fact that AR continues to be the primary target responsible for metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Eva, Guthrie, Troy, Tan, Winston
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167156/
https://www.ncbi.nlm.nih.gov/pubmed/25062956
http://dx.doi.org/10.1186/1471-2490-14-55

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167156/
https://www.ncbi.nlm.nih.gov/pubmed/25062956
http://dx.doi.org/10.1186/1471-2490-14-55

Ejemplares similares